Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Guardant Liquid Biopsy Test Approved as CDx for Targeted Colorectal Cancer Drugs
October 17, 2023
- Telomelysin-Radiation Combo Hits Mark in PII Esophageal Cancer Study: Oncolys
October 17, 2023
- Meiji/KM’s XBB.1.5-Tailored COVID Jab to Enter Pediatric PIII Study
October 17, 2023
- EU Panel Backs Astellas’ Hot Flash Drug
October 17, 2023
- Oral Flu Drug Prescriptions 17 Times Higher than Pre-COVID: September Survey
October 16, 2023
- Japan Pharma Market to Contract after 2027 on Biosimilar Influx: Fuji Keizai
October 13, 2023
- Shonan iPark Looks to Woo Korean Firms by Partnering with Govt: Chief
October 13, 2023
- Viatris to Discontinue 28 APIs/48 Products for Supply, Productivity Reasons
October 12, 2023
- Healios Grabs Worldwide Rights to Athersys’ Cell Therapy in ARDS
October 12, 2023
- Astellas, Shared Lab Operators Link Up on Life Science Ecosystem
October 12, 2023
- Donanemab’s Limited Duration of Dosing Benefits Patients on Safety Front: Lilly CSO
October 11, 2023
- Japan Ethical Drug Sales Surge 8.1% in August: Crecon
October 10, 2023
- Kyowa Kirin to Acquire Orchard to Forge Ahead in Gene Therapy
October 6, 2023
- Hyperhidrosis Drug Ecclock Filed in South Korea: Kaken
October 6, 2023
- Opdivo Snatches Back Top Spot in Japan Sales Ranking in September: Encise
October 6, 2023
- Sawai Bags CML Nod for Sprycel Generic
October 5, 2023
- JCR to Explore Best Opportunities for Overseas Alliance on JR-171: Exec
October 5, 2023
- Manlio Florenzano Takes Helm of Sandoz Japan as Spin-Off Completes
October 5, 2023
- Nippon Kayaku Buys Stake in Adlai to Drive Cancer Drug Collab
October 5, 2023
- CSL/Alfresa Roll Out Home Delivery Service of Hemophilia Drugs
October 4, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…